Pipeline — registered trials by phase
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Moderna is lead sponsor; 0 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-09-30Current report (material event)
- 8-K2026-09-01Current report (material event)
- SCHEDULE 13G2026-08-12SCHEDULE 13G
- SCHEDULE 13G/A2026-08-06SCHEDULE 13G/A
- 10-Q2026-07-31Quarterly report
- 8-K2026-07-31Current report (material event)
- SCHEDULE 13G/A2026-07-24SCHEDULE 13G/A
- 8-K2026-07-08Current report (material event)
- 8-K2026-05-11Current report (material event)
- 10-Q2026-05-01Quarterly report
- 8-K2026-05-01Current report (material event)
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- DEFA14A2026-03-16DEFA14A
- DEF 14A2026-03-16Proxy statement
- ARS2026-03-16Annual report to holders
- 8-K2026-03-05Current report (material event)
- S-82026-02-20Employee stock plan
- 10-K2026-02-20Annual report
- 8-K2026-02-13Current report (material event)
- 8-K2026-02-11Current report (material event)
- SCHEDULE 13G/A2026-02-09SCHEDULE 13G/A
- SCHEDULE 13G/A2026-02-06SCHEDULE 13G/A
- SCHEDULE 13G2026-02-05SCHEDULE 13G
- 8-K2026-01-12Current report (material event)
- 8-K2026-01-05Current report (material event)
- SC TO-I/A2025-12-16SC TO-I/A
- 8-K2025-11-24Current report (material event)
- 8-K2025-11-20Current report (material event)
- SC TO-I/A2025-11-18SC TO-I/A
- 8-K2025-11-13Current report (material event)
- SC TO-I2025-11-13SC TO-I
- SC TO-C2025-11-12SC TO-C
- SC TO-C2025-11-06SC TO-C
- 10-Q2025-11-06Quarterly report
- 8-K2025-11-06Current report (material event)
- SCHEDULE 13G/A2025-11-05SCHEDULE 13G/A
- SC TO-C2025-10-21SC TO-C
- DEFA14A2025-10-20DEFA14A
- DEF 14A2025-10-15Proxy statement
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.